Refractory and Relapsed B Cell Acute Leukemia Clinical Trial
Official title:
The Phase I Efficacy and Safety Clinical Study of CD19/CD22-Dual-STAR-T Cells in Relapsed and Refractory B-ALL.
| Verified date | May 2022 |
| Source | Hebei Yanda Ludaopei Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is a single center, single arm, open-lable phase I study to determine the safety and efficacy of CD19/CD22-Dual-STAR-T cells in patients with refractory and relapsed B cell acute leukemia .
| Status | Terminated |
| Enrollment | 2 |
| Est. completion date | May 1, 2022 |
| Est. primary completion date | May 1, 2022 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 1 Year to 70 Years |
| Eligibility | Inclusion Criteria: 1. Ages 1 to 70 years. 2. Prelapsed and refractorys B-ALL at least with one of the following conditions: - Could not achieve CR after 2course of chemotherapy. - Could not achieve CR or relapse after first-line or multi-line salvage chemotherapy, or MRD=0.1%. - Relapse within 12 months after first remission or MRD=0.1%. - Relapse after achieved CR in allogeneic hematopoietic stem cell transplantation (HSCT), or MRD=0.1%. - For Ph + patients: Failure to tolerate TKI or TKI treatment failure could be enrolled. 3. CD19 and/or CD22 positive within 3 months. 4. ECOG 0-2. 5. Estimated life expectancy = 3 months. 6. Women of childbearing age must receive a pregnancy test within 7 days prior to initiation of treatment and the results are negative; male and female patients with fertility must use an effective contraceptive to ensure 12 months after discontinuation of treatment during the study period not pregnant inside. 7. Patients who voluntarily sign informed consent and are willing to comply with treatment plans, visit arrangements, laboratory tests and other research procedures. Exclusion Criteria: 1. Active infections that are difficult to control 2. HBV-DNA HCV-RNA and HIV ,either of which is positive 3. Central nervous system leukemias that is symptomatic or uncontrolled by systemic chemotherapy and intrathecal chemotherapy 4. Patients are receiving anti-GVHD treatment within 4 weeks of before screening. 5. Performed major surgery within 4 weeks before screening. 6. Patients have received chemotherapy within 7 days of screening. 7. Experimental drugs were used within 4 weeks before screening. 8. Received allogeneic cell therapy within 6 weeks prior to cell infusion. 9. Patients have history of epilepsy or central nervous system diseases. 10. Severe thyroid dysfunction 11. Patients with active autoimmune disease. 12. Pregnant or lactating women. 13. The patient does not agree to use effective contraception during treatment and for the following 12 months; 14. The researchers found that it was unsuitable for the recipients to be enrolled. |
| Country | Name | City | State |
|---|---|---|---|
| China | Hebei Yanda Ludaopei Hospital | Sanhe | Hebei |
| Lead Sponsor | Collaborator |
|---|---|
| Hebei Yanda Ludaopei Hospital | China Immunotech (Beijing) Biotechnology Co., Ltd. |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Percentage of participants with adverse events. | Percentage of participants with adverse events. | 12 months | |
| Secondary | Objective Remission Rate(ORR) | The percentage of participants who achieved complete remission(CR) and CR in over all participants. | 12 months | |
| Secondary | Proliferation ratio of Dual-STAR-T cells | 12 months |